Bernard Prudhon
Paris, 75013, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations.
Journal: Molecular therapy. Nucleic acids
Published: March 28, 2022
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.
Journal: Molecular therapy. Nucleic acids
Published: August 11, 2021
Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model.
Journal: Scientific reports
Published: November 14, 2018
Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
Journal: EMBO molecular medicine
Published: December 17, 2017
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy.
Journal: Molecular therapy. Nucleic acids
Published: May 06, 2017
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing.
Journal: Molecular therapy. Nucleic acids
Published: April 21, 2016
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls.
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls.
Journal: Current gene therapy
Published: November 06, 2014
Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders.
Journal: Journal of neuropathology and experimental neurology
Published: August 23, 2013
Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.
Journal: Human mutation
Published: November 13, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026